Ideaya Biosciences Inc (IDYA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.94B
Last updated: Nov 17, 2026 at 4:33 PM ET
Ideaya Biosciences Inc (IDYA) Statistics
Ideaya Biosciences (IDYA) has a market cap of $2.94B and an enterprise value of $2.67B. It kept -1149.62% of revenue as net income over the last 12 months. Revenue fell 82.99% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 8.91% below the market cap, as cash exceeds debt.
| Market Cap | $2.94B |
|---|---|
| Enterprise Value | $2.67B |
| Latest price (Nov 17, 2026) | $27.40 |
Key Dates
The next earnings report is expected on Feb 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 3, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 77.2x and 2.6x. Its year-end P/S ranged from 14.0x to 320.7x from 2020 to 2025.
| P/S Ratio | 77.2x |
|---|---|
| Forward P/S | 69.2x |
| P/B Ratio | 2.6x |
Price Statistics
The stock is down 14.75% over 52 weeks and trades 21.83% below its 50-day average.
| Beta (1Y) | 1.06 |
|---|---|
| 52-Week Change | -14.75% |
| 1-Month Change | -18.96% |
| 3-Month Change | -29.51% |
| 6-Month Change | -3.25% |
| 5-Year Change | +49.07% |
| Total Return (1Y) | -14.75% |
| Total Return (3Y CAGR) | -3.37% |
| Total Return (5Y CAGR) | +3.17% |
| Return vs SPY (1Y) | -30.28% |
| Max Drawdown (1Y) | -35.50% |
| Max Drawdown (3Y) | -69.23% |
| Sharpe Ratio (1Y) | -0.45 |
| Correlation with SPY (1Y) | 0.32 |
| 50-Day Average | $35.05 |
| 200-Day Average | $33.81 |
| 52-Week Range | $26.81 to $42.68 |
| RSI (14 Days) | 29.0 |
| Average Volume (20 Days) | 1.11M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 9.04x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 9.04x |
|---|---|
| Quick Ratio | 9.04x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -38.46% over the last 12 months, against a 5-year average of -17.70%.
| Return on Equity (ROE) | -38.46% |
|---|---|
| Return on Assets (ROA) | -34.54% |
| ROE (5Y Average) | -17.70% |
| ROA (5Y Average) | -16.05% |
| ROIC (5Y Average) | -8.78% |
| Asset Turnover | 0.03x |
Scores
IDYA has an Altman Z-Score of 12.02, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 12.02 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $36.53M over the last 12 months.
| Revenue | $36.53M |
|---|---|
| Revenue Growth (YoY) | -82.99% |
| Gross Profit | $36.53M |
| Operating Income | -$463.04M |
| Pretax Income | -$407.75M |
| Net Income | -$420.01M |
| Reported EPS (TTM) | -$4.49 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 89.34% of the $1.22B in total assets.
| Cash and Equivalents | $261.45M |
|---|---|
| Total Debt | $0 |
| Net Cash | $261.45M |
| Net Cash Per Share | $2.54 |
| Working Capital | $775.56M |
| Shareholder Equity | $1.09B |
| Book Value Per Share | $10.61 |
| Total Assets | $1.22B |
| Total Liabilities | $123.96M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $2.44M of capital spending, operating cash flow left -$349.80M of free cash flow.
| Operating Cash Flow | -$347.36M |
|---|---|
| Capital Expenditures | $2.44M |
| Free Cash Flow | -$349.80M |
| FCF Per Share | -$3.63 |
| Depreciation and Amortization | $5.89M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -1267.38%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -1267.38% |
| Pretax Margin | -1116.04% |
| Net Margin | -1149.62% |
| FCF Margin | -957.43% |
Growth
Revenue grew 62.54% a year over 3 years.
| Revenue Growth (3Y CAGR) | +62.54% |
|---|---|
| Revenue Growth (5Y CAGR) | +62.11% |
| Book Value Per Share Growth (2Y CAGR) | +10.14% |
| Tangible Book Per Share Growth (2Y CAGR) | +10.14% |
Dividends and Yields
IDYA does not pay a dividend. Its free cash flow yield is -12.40%.
| FCF Yield | -12.40% |
|---|---|
| Buyback Yield | -12.68% |
| Shareholder Yield | -12.68% |
Peer Position
Against 7 similar companies, IDYA has the 3rd highest P/S.
P/S RatioPeer median 13.1x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -31.77%
| P/S Ratio | 77.2x vs 13.1x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -82.99% vs -31.77% median |
Analyst Forecast
Consensus estimates put revenue growth at -24.57% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -24.57% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About IDYA
What is IDYA's market cap?
Ideaya Biosciences has a market cap of $2.94B. Its enterprise value, which adds debt and subtracts cash, is $2.67B.
How many shares of IDYA are outstanding?
Ideaya Biosciences has 102.94M shares outstanding. The count is up 16.29% from a year earlier.
Does IDYA pay a dividend?
No. Ideaya Biosciences does not pay a dividend.
How much debt does IDYA have?
Ideaya Biosciences has $0 of total debt and $261.45M of cash and equivalents, a net cash position of $261.45M.
IDYA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors